GMP IPO Watch
Kotak Healthcare Fund
Direct Plan · Growth Option · Kotak Mahindra Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | -2.55% | -0.74% | 249 of 255 |
| 1M | -4.43% | -3.43% | 198 of 254 |
| 3M | +2.02% | -2.81% | 36 of 251 |
| 6M | +23.88% | +5.52% | 9 of 251 |
| YTD | +24.97% | +0.06% | 4 of 255 |
| 1Y | +22.49% | +1.29% | 7 of 228 |
| 2Y | +10.55% | -0.39% | 14 of 183 |
| INCEPTION | +20.99% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.30% | +25.58% | -15.71% | 73% | 30% |
| 6M | +9.83% | +34.99% | -12.79% | 73% | 31% |
| 1Y | +13.50% | +42.47% | -6.20% | 86% | 38% |
| 2Y | +14.20% | +19.55% | +8.08% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity96.99%
- Debt0.00%
- Cash3.01%
- Other0.00%
Market Cap Split
- Large Cap33.44%
- Mid Cap19.62%
- Small Cap45.63%
- Others1.31%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 45.52 | 42.02 |
| P/B | 6.93 | 6.30 |
| Price / Sales | 6.74 | 6.07 |
| Price / Cash Flow | 34.64 | 31.31 |
| Dividend Yield (%) | 0.42 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals and Biotechnology | 13.21% | -0.75% |
| Divis Laboratories | Pharmaceuticals and Biotechnology | 9.35% | +0.10% |
| Molbio Diagnostics | Equity | 5.08% | +0.55% |
| Torrent Pharmaceuticals | Pharmaceuticals and Biotechnology | 4.65% | -0.10% |
| Acutaas Chemicals | Pharmaceuticals and Biotechnology | 4.17% | +0.26% |
| Max Healthcare Institute | Equity | 3.61% | -0.73% |
| Cipla | Pharmaceuticals and Biotechnology | 3.26% | -0.41% |
| Park Medi World | Equity | 3.17% | -0.19% |
| Gland Pharma | Pharmaceuticals and Biotechnology | 3.16% | +0.12% |
| Yatharth Hospital | Equity | 3.12% | -0.13% |
| Triparty Repo | Reverse Repo / TREPS | 3.01% | — |
| Apollo Hospitals | Equity | 2.97% | -0.28% |
| Sai Life Sciences | Pharmaceuticals and Biotechnology | 2.96% | -0.08% |
| Laurus Labs | Pharmaceuticals and Biotechnology | 2.88% | +0.39% |
| Mankind Pharma | Pharmaceuticals and Biotechnology | 2.73% | -0.11% |
View all 37 holdings
| Krishna Institute of Medical Sciences | Equity | 2.71% | +0.25% |
| Marksans Pharma | Pharmaceuticals and Biotechnology | 2.44% | -0.07% |
| Anthem Biosciences | Pharmaceuticals and Biotechnology | 2.34% | +0.01% |
| Fortis Healthcare | Equity | 2.33% | -0.62% |
| Prasol Chemicals | Chemicals and Petrochemicals | 2.24% | — |
| Ajanta Pharma | Pharmaceuticals and Biotechnology | 1.97% | -0.14% |
| Rubicon Research | Pharmaceuticals and Biotechnology | 1.96% | -0.41% |
| Emcure Pharmaceuticals | Pharmaceuticals and Biotechnology | 1.77% | +0.20% |
| Aurobindo Pharma | Pharmaceuticals and Biotechnology | 1.72% | +0.15% |
| Viyash Scientific | Pharmaceuticals and Biotechnology | 1.71% | -0.30% |
| Orchid Pharma | Pharmaceuticals and Biotechnology | 1.57% | -0.07% |
| Corona Remedies | Pharmaceuticals and Biotechnology | 1.52% | -0.08% |
| Innova Captab | Pharmaceuticals and Biotechnology | 1.41% | +0.33% |
| Jubilant Ingrevia | Chemicals and Petrochemicals | 1.35% | -0.14% |
| Jubilant Pharmova | Pharmaceuticals and Biotechnology | 1.25% | +0.10% |
| Rainbow Childrens Medicare | Equity | 1.11% | -0.18% |
| Dr. Lal Path Labs | Equity | 1.06% | -0.05% |
| Zydus Life Science | Pharmaceuticals and Biotechnology | 1.06% | -0.07% |
| Metropolis Healthcare | Equity | 0.98% | -0.16% |
| Lupin | Pharmaceuticals and Biotechnology | 0.98% | -0.16% |
| Pfizer | Pharmaceuticals and Biotechnology | 0.89% | -0.27% |
| Net Current Assets/(Liabilities) | Equity | -1.70% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 18.30 | 14.95 | High Volatility |
What is this?
Risk as measured by standard deviation is a statistical measure that quantifies the amount of variation or dispersion in a set of data points relative to its mean (average).
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.40 | 0.80 | Good Risk Adjusted Returns |
What is this?
Higher the value means that fund has been able to give better returns for the amount of risk taken. It helps investors understand the return of an investment compared to its risk, showing whether the returns are due to intelligent investing or simply taking on excess risk. It is calculated by subtracting the risk-free return, defined as an Indian Government Bond, from the fund's returns, and then dividing by the standard deviation of returns.
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.96 | 1.40 | Good Risk Adjusted Returns |
What is this?
The Sortino Ratio is a financial metric used to measure the risk-adjusted return of an investment. It's a modification of the Sharpe Ratio but with a key difference; it only considers downside risk (the risk of negative returns), rather than total volatility. This means it focuses on how well an investment performs relative to the volatility that leads to losses, ignoring the volatility that results in gains. The idea is that investors are primarily concerned with minimizing losses, and positive volatility is generally seen as a good thing.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.02 | 0.96 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+117.34% | +57.47% | — | +30.27% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+27.93% | +21.56% | +10.16% | +8.96% |
|
Motilal Oswal Active Momentum Fund
Direct Plan · Growth
|
+27.13% | — | — | +28.60% |
|
Franklin Asian Equity Fund
Regular Plan · IDCW
|
+26.32% | +19.68% | +4.65% | +4.11% |
|
Motilal Oswal Special Opportunities Fund
Direct Plan · Growth
|
+22.15% | — | — | +22.04% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+21.62% | +28.86% | — | +28.94% |
|
Edelweiss Recently Listed IPO Fund
Regular Plan · Growth
|
+20.42% | +15.88% | +9.04% | +14.82% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+20.18% | +34.39% | — | +37.86% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+19.77% | — | — | +9.91% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+19.09% | +16.92% | +11.79% | +15.53% |
More From Kotak Mahindra Asset Management Company Limited.
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Kotak US Specific Equity Passive FOF
Direct Plan · Growth
|
+34.43% | +32.13% | +21.67% | +21.22% |
|
Kotak Global Emerging Market Overseas Equity Active FOF
Direct Plan · Growth
|
+33.80% | +28.00% | +12.51% | +9.60% |
|
Kotak Global Innovation Overseas Equity Active FOF
Direct Plan · Growth
|
+28.81% | +27.62% | +11.00% | +10.06% |
|
Kotak Silver ETF Fund of Fund
Direct Plan · Growth
|
+28.23% | +44.16% | — | +33.93% |
| Kotak Silver ETF | +27.39% | +45.00% | — | +34.17% |
| KOTAK GOLD ETF | +18.35% | +34.86% | +24.31% | +14.68% |
|
Kotak Gold Fund
Direct Plan · Growth
|
+18.06% | +34.50% | +23.97% | +10.86% |
|
Kotak MNC Fund
Direct Plan · IDCW Option
|
+16.71% | — | — | +11.77% |
|
Kotak Special Opportunities Fund
Direct Plan · Growth
|
+15.18% | — | — | +6.22% |
|
Kotak Manufacture in India Fund
Direct Plan · IDCW Option
|
+13.76% | +19.40% | — | +19.95% |
About This Scheme
Investment Objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved .
Stated Asset Allocation
Investments Indicative Allocation Equity and Equity Related Instruments of companies engaged in Pharma, healthcare & allied sectors - 80%-100% Other Equity and Equity Related Instruments of companies -0%-20% Debt and Money Market Instruments - 0%-20% Units of Gold/Silver ETF - 0-20% Units of InvITs - 0%-10%
Exit Load
For redemption / switch out within 30 days from the date of allotment: 0.5% If units are redeemed or switched out on or after 30 days from the date of allotment: NIL Units issued on reinvestment of IDCW shall not be subject to entry and exit load. Any exit load charged (net off Goods and Services tax, if any) shall be credited back to the Scheme.
Fund Managers
FM 1 Mr. Dhananjay Tikariha, FM 2 Mr. Abhishek Bisen
FM 1 Fund Manager is the Co-Fund Manager for equity investments of the scheme. FM 2 Fund Manager is the Fund Manager for debt investment of the Scheme.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.